Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
Public ClinicalTrials.gov record NCT04120194. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age
Study identification
- NCT ID
- NCT04120194
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novavax
- Industry
- Enrollment
- 2,654 participants
Conditions and interventions
Conditions
Interventions
- NanoFlu Biological
- Fluzone Quadrivalent Biological
Biological
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2019
- Primary completion
- Oct 28, 2020
- Completion
- Dec 12, 2020
- Last update posted
- May 5, 2023
2019 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US135 | Hollywood | Florida | 33024 | — |
| US045 | Savannah | Georgia | 31406 | — |
| US013 | Stockbridge | Georgia | 30281 | — |
| US012 | Meridian | Idaho | 83642 | — |
| US032 | Nampa | Idaho | 83687 | — |
| US003 | Lenexa | Kansas | 66219 | — |
| US138 | Rockville | Maryland | 20854 | — |
| US025 | Norfolk | Nebraska | 68701 | — |
| US018 | Omaha | Nebraska | 68134 | — |
| US056 | Binghamton | New York | 13901 | — |
| US017 | Endwell | New York | 13760 | — |
| US030 | Cleveland | Ohio | 44122 | — |
| US053 | Oklahoma City | Oklahoma | 73112 | — |
| US044 | Warwick | Rhode Island | 02886 | — |
| US079 | Mt. Pleasant | South Carolina | 29464 | — |
| US050 | Dakota Dunes | South Dakota | 57049 | — |
| US029 | Nashville | Tennessee | 37203 | — |
| US004 | San Antonio | Texas | 78229 | — |
| US073 | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04120194, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04120194 live on ClinicalTrials.gov.